The genotyping market in Middle East & Africa is expected to grow from US$ 1,141.17 million in 2022 to US$ 3,176.29 million by 2028. It is estimated to grow at a CAGR of 18.6% from 2022 to 2028.
Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases such as cancer, diabetes, and Alzheimer's.
According to the International Diabetes Federation (IDF) Consortium 2019, type 2 diabetes (T2D) is one of the leading causes of death worldwide, accounting for 4.2 million deaths in 2019. According to the same research, Iran ranks third among 20 countries in the Middle East and North Africa (MENA) in terms of the number of adults with diabetes (5.4 million), estimated that about 9.2 million Iranians may catch the disease by 2030. Type 2 diabetes is a complex metabolic illness caused by genetic and non-genetic (environmental) factors. The heritability of T2D varies between 20% and 80%, indicating that genetic factors play a significant part in the disease's development; the disease's heritable component is polygenic, meaning that multiple genes and their variations contribute to an increased risk of T2D development. The introduction of high-throughput genotyping technologies has greatly advanced our understanding of the genetic components of complex disorders, such as T2D.
Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification. Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves. More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases will be one of the key factors driving the growth of the genotyping markets during the forecast period.
Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases such as cancer, diabetes, and Alzheimer's.
According to the International Diabetes Federation (IDF) Consortium 2019, type 2 diabetes (T2D) is one of the leading causes of death worldwide, accounting for 4.2 million deaths in 2019. According to the same research, Iran ranks third among 20 countries in the Middle East and North Africa (MENA) in terms of the number of adults with diabetes (5.4 million), estimated that about 9.2 million Iranians may catch the disease by 2030. Type 2 diabetes is a complex metabolic illness caused by genetic and non-genetic (environmental) factors. The heritability of T2D varies between 20% and 80%, indicating that genetic factors play a significant part in the disease's development; the disease's heritable component is polygenic, meaning that multiple genes and their variations contribute to an increased risk of T2D development. The introduction of high-throughput genotyping technologies has greatly advanced our understanding of the genetic components of complex disorders, such as T2D.
Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification. Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves. More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases will be one of the key factors driving the growth of the genotyping markets during the forecast period.
Middle East & Africa Genotyping Market Segmentation
The Middle East & Africa genotyping market is segmented by products and services, technology, application, end user, and country.- Based on products and services, the market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment is dominating the market in 2022.
- Based on technology, the market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF) mass spectrometry, polymerase chain reaction (PCR), and others. The PCR segment is dominating the market in 2022.
- Based on application, the market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment is dominating the market in 2022.
- Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is dominating the market in 2022.
- Based on country, the market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of the Middle East & Africa. Further, the Rest of the Middle East & Africa is dominating the market in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Genotyping Market - Market Landscape
5. MEA Genotyping Market- Key Market Dynamics
6. Genotyping Market- MEA Analysis
7. MEA Genotyping Market- by Product and Services
8. MEA Genotyping Market- by Technology
9. MEA Genotyping Market-by Application
10. MEA Genotyping Market- by End User
11. MEA Genotyping Market- Country Analysis
12. MEA Genotyping Market Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioTek Instruments, Inc.
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Integrated DNA Technologies, Inc.
- MERCK KGaA
- QIAGEN
- Thermo Fisher Scientific Inc
- TrimGen Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 159 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1141.17 Million |
| Forecasted Market Value ( USD | $ 3176.29 Million |
| Compound Annual Growth Rate | 18.6% |
| Regions Covered | Africa, Middle East |
